EP2787990A4 - Traitement de l'amyloïdose au moyen de composés qui régulent la stabilisation de rétromères - Google Patents

Traitement de l'amyloïdose au moyen de composés qui régulent la stabilisation de rétromères

Info

Publication number
EP2787990A4
EP2787990A4 EP12854791.6A EP12854791A EP2787990A4 EP 2787990 A4 EP2787990 A4 EP 2787990A4 EP 12854791 A EP12854791 A EP 12854791A EP 2787990 A4 EP2787990 A4 EP 2787990A4
Authority
EP
European Patent Office
Prior art keywords
retromer
amyloidosis
stabilization
regulate
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12854791.6A
Other languages
German (de)
English (en)
Other versions
EP2787990A1 (fr
Inventor
Dagmar Ringe
Gregory A Petsko
Scott A M D Small
Vincent Mecozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Brandeis University
Original Assignee
Columbia University in the City of New York
Brandeis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York, Brandeis University filed Critical Columbia University in the City of New York
Publication of EP2787990A1 publication Critical patent/EP2787990A1/fr
Publication of EP2787990A4 publication Critical patent/EP2787990A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP12854791.6A 2011-12-05 2012-12-04 Traitement de l'amyloïdose au moyen de composés qui régulent la stabilisation de rétromères Withdrawn EP2787990A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567023P 2011-12-05 2011-12-05
PCT/US2012/067704 WO2013085877A1 (fr) 2011-12-05 2012-12-04 Traitement de l'amyloïdose au moyen de composés qui régulent la stabilisation de rétromères

Publications (2)

Publication Number Publication Date
EP2787990A1 EP2787990A1 (fr) 2014-10-15
EP2787990A4 true EP2787990A4 (fr) 2015-09-02

Family

ID=48574799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12854791.6A Withdrawn EP2787990A4 (fr) 2011-12-05 2012-12-04 Traitement de l'amyloïdose au moyen de composés qui régulent la stabilisation de rétromères

Country Status (4)

Country Link
US (2) US20140288145A1 (fr)
EP (1) EP2787990A4 (fr)
CA (1) CA2857964A1 (fr)
WO (1) WO2013085877A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184454A1 (en) * 2013-01-11 2016-06-30 Asa Abeliovich Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
EP3392244A1 (fr) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
NZ735998A (en) 2015-04-03 2024-08-30 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
NZ740186A (en) 2015-08-12 2024-07-05 Incyte Holdings Corp Salts of an lsd1 inhibitor
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
AU2020250879A1 (en) * 2019-04-01 2021-10-28 Ospedale San Raffaele Srl Aminoguanidine hydrazones as retromer stabilizers useful for treating neurological diseases
EP4085909A1 (fr) * 2021-05-06 2022-11-09 Consejo Superior de Investigaciones Cientificas Procédés et compositions pour le traitement de troubles caractérisés par un dysfonctionnement de kidins220 chez un sujet
KR102708752B1 (ko) * 2021-11-05 2024-09-23 서울대학교산학협력단 레트로머 안정제를 포함하는 당뇨병 매개 신경퇴행성질환의 예방, 개선 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214482A1 (en) * 2005-11-15 2008-09-04 Scott Small Retromer-based assays and methods for treating alzheimer's disease
WO2008151288A2 (fr) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals Inc. Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046585A2 (fr) * 2003-11-07 2005-05-26 The Trustees Of Columbia University In The City Of New York Dosage a base de vps35 et procedes de traitement de la maladie d'alzheimer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214482A1 (en) * 2005-11-15 2008-09-04 Scott Small Retromer-based assays and methods for treating alzheimer's disease
WO2008151288A2 (fr) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals Inc. Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013085877A1 *
SUZANNE J. NORWOOD ET AL: "Assembly and Solution Structure of the Core Retromer Protein Complex", TRAFFIC, vol. 12, no. 1, 15 October 2010 (2010-10-15), pages 56 - 71, XP055203031, ISSN: 1398-9219, DOI: 10.1111/j.1600-0854.2010.01124.x *

Also Published As

Publication number Publication date
CA2857964A1 (fr) 2013-06-13
US20150361063A1 (en) 2015-12-17
US20140288145A1 (en) 2014-09-25
WO2013085877A1 (fr) 2013-06-13
EP2787990A1 (fr) 2014-10-15

Similar Documents

Publication Publication Date Title
EP2787990A4 (fr) Traitement de l'amyloïdose au moyen de composés qui régulent la stabilisation de rétromères
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
EP2723384A4 (fr) Traitement de protéinopathies
HK1197400A1 (zh) 治療 的化合物
ZA201307036B (en) Treatment of solid tumours
HK1198812A1 (en) Treatment of rhinitis
IL228630A0 (en) Compounds for the treatment of the metabolic syndrome
IL231907B (en) Compounds and compositions for the treatment of transthyretin-related amyloidosis
EP2709665A4 (fr) Traitement du psoriasis
EP2694465A4 (fr) Composés ortho-fluoro substitués pour traiter les maladies métaboliques
GB201120644D0 (en) Herbicidal uses of compounds
EP2903643A4 (fr) Traitement d'affections psychiatriques
IL231143A0 (en) Treatment of rhinitis
EP2785723A4 (fr) Difluorométhylation de composés insaturés
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders
GB201119533D0 (en) Compounds for the treatment of neoplasia
GB201119458D0 (en) Compositions for treatment of sleep disorders
ZA201204069B (en) Treatment of water
GB201118065D0 (en) Treatment of movement disorders
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201105302D0 (en) Treatment of acidosis
GB201212717D0 (en) Treatment of musculoskeletal conditions
EP2696872A4 (fr) Traitement du glaucome

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150803

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/195 20060101ALI20150728BHEP

Ipc: A61K 31/38 20060101AFI20150728BHEP

Ipc: A61K 31/155 20060101ALI20150728BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161024

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170304